Stockscreener 앱 받기
35.49
3.17%
1.09
시간 외 거래:
35.43
-0.06
-0.17%
Sionna Therapeutics Inc 주식(SION)의 최신 뉴스
Sionna Stock Is Up 144% This Past Year. Is the Biotech a Buy as One Fund Makes a $7 Million Bet? - AOL.com
This Investor Sold $5 Million of a Biotech Stock Up 118% in a Year, but Here's Why It Still Seems Bullish on Shares - AOL.com
Superstring Capital Invests in Sionna Therapeutics: Q4 2025 Filing DetailsNews and Statistics - IndexBox
'This is one of your classic, binary biotech stocks': Baral on Sionna Therapeutics - BNN Bloomberg
This investor offloaded $5 million worth of a biotech stock that surged 118% over the past year, yet there are still reasons to believe they remain optimistic about its future performance. - Bitget
Braidwell LP Has $9.24 Million Stake in Sionna Therapeutics, Inc. $SION - MarketBeat
Analysts Offer Insights on Healthcare Companies: Sionna Therapeutics, Inc. (SION) and Health Catalyst (HCAT) - The Globe and Mail
Sionna Therapeutics, Inc. $SION Shares Sold by Atlas Venture Life Science Advisors LLC - MarketBeat
SION: Advancing NBD1 stabilizers for cystic fibrosis with pivotal data expected by mid-2026 - TradingView
Analysts Are Bullish on These Healthcare Stocks: Sionna Therapeutics, Inc. (SION), Privia Health Group (PRVA) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: GH Research (GHRS) and Sionna Therapeutics, Inc. (SION) - The Globe and Mail
Loss Report: Is now the right time to enter Sionna Therapeutics IncMarket Risk Summary & Free Daily Entry Point Trade Alerts - baoquankhu1.vn
Sionna Therapeutics chief legal officer sells shares for $347,018 By Investing.com - Investing.com Australia
Sionna Therapeutics chief legal officer sells shares for $347,018 - Investing.com
TD Asset Management Inc Grows Position in Sionna Therapeutics, Inc. $SION - MarketBeat
Reassessing Sionna Therapeutics (SION) Valuation After Recent Share Price Pullback And CF Pipeline Progress - simplywall.st
UBS Maintains Buy on Sionna Therapeutics, Inc. (SION) March 02, 2026 - Meyka
SION: NBD1 stabilization could transform CF care, with dual and add-on therapies advancing in clinical trials - TradingView
Sionna Therapeutics (NASDAQ:SION) Earns Buy Rating from BTIG Research - MarketBeat
Sionna Therapeutics (NASDAQ:SION) Shares Gap DownShould You Sell? - MarketBeat
Sionna Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Guggenheim raises Sionna Therapeutics stock price target to $50 By Investing.com - Investing.com Canada
Sionna Therapeutics Inc maintains strong cash position with about $310.3 million in cash and cash equivalents, expected to fund operations into 2028 - marketscreener.com
Sionna Therapeutics Inc Maintains Strong Cash Position With About $310.3 Million In Cash And Cash Equivalents, Expected To Fund Operations Into 2028 - TradingView
Form S-3ASR Sionna Therapeutics, - StreetInsider
Sionna Therapeutics Q4 Net Loss Narrows - marketscreener.com
Sionna Therapeutics (SION) outlines NBD1-focused cystic fibrosis drug pipeline - Stock Titan
Earnings Flash (SION) Sionna Therapeutics Posts Q4 Net Loss $0.46 a Share, vs. FactSet Est of $0.55 Loss - marketscreener.com
Sionna Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - Bitget
Sionna Therapeutics 10-K: $0 Revenue, $(1.88) EPS - TradingView
Sionna Therapeutics (Nasdaq: SION) posts 2025 loss, ends year with $310.3M cash - Stock Titan
Assessing Sionna Therapeutics (SION) Valuation As Premium P/B Meets Cooling Share Price Momentum - Yahoo Finance
Sionna Therapeutics (NASDAQ:SION) Rating Increased to Strong-Buy at Lifesci Capital - MarketBeat
JPMorgan Chase & Co. Cuts Stake in Sionna Therapeutics, Inc. $SION - MarketBeat
Sionna Therapeutics, Inc. (NASDAQ:SION) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Citizens Initiates Coverage of Sionna Therapeutics (SION) with Market Outperform Recommendation - Nasdaq
Sionna Therapeutics (NASDAQ:SION) Coverage Initiated by Analysts at Citizens Jmp - MarketBeat
Market Recap: Is FIVE in a consolidation phase2025 EndofYear Setup & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Cystic fibrosis drug developer Sionna heads to key March investor events - Stock Titan
Sionna Therapeutics to Participate in Upcoming March 2026 Investor Conferences - The Manila Times
Sionna Therapeutics, Inc. (SION) Stock Analysis: A High-Stakes Bet on Biotech Innovation with 20.13% Upside Potential - DirectorsTalk Interviews
Is Sionna Therapeutics Inc. still a buy after recent gainsJuly 2025 Trade Ideas & Stepwise Trade Execution Plans - mfd.ru
Fed Meeting: Will Sionna Therapeutics Inc outperform tech stocks2025 AllTime Highs & Community Trade Idea Sharing Platform - baoquankhu1.vn
Sionna Therapeutics Maps Mid-2026 CF Catalysts, Highlights NBD1 Stabilizers at Guggenheim Summit - Yahoo Finance
2026 Milestones in Focus as Sionna Therapeutics Pursues NBD1 Stabilization for CFTR - AD HOC NEWS
Sionna Therapeutics, Inc. (SION) Investor Outlook: Analyzing a 19% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
SION: NBD1 stabilizer programs target major CF mutations, with pivotal data expected mid-2026 - TradingView
Can Sionna Therapeutics Inc. stock outperform in 2025 bull marketJuly 2025 Breakouts & Technical Confirmation Alerts - mfd.ru
Analysts Offer Insights on Healthcare Companies: Sionna Therapeutics, Inc. (SION) and Incyte (INCY) - The Globe and Mail
What’s the MACD signal for Sionna Therapeutics Inc.July 2025 Outlook & Risk Adjusted Buy/Sell Alerts - mfd.ru
Volume Recap: Should you avoid Sionna Therapeutics Inc stock right nowEarnings Miss & Growth-Oriented Investment Plans - baoquankhu1.vn
Orbimed Advisors Llc Sells 29,063 Shares of Sionna Therapeutics (NASDAQ:SION) Stock - Defense World
Peter Thompson Sells 29,063 Shares of Sionna Therapeutics (NASDAQ:SION) Stock - Defense World
Sionna Therapeutics (NASDAQ:SION) Shares Down 14.6% on Insider Selling - Defense World
Sionna Therapeutics (NASDAQ:SION) Trading Down 14.6% Following Insider Selling - MarketBeat
OrbiMed Advisors LLC sells Sionna Therapeutics (SION) stock worth $1.37m - Investing.com Australia
1.20%
0.06%
자본화:
|
볼륨(24시간):